Faslodex 250 mg oplossing voor injectie
As listed in the register: Faslodex 250 mg oplossing voor injectie
250 mg · oplossing voor injectie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Fulvestrant
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (CLIGAVYX). It describes the substance, not this exact product.
Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen.
Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.
Although fulvestrant is partly metabolized by CYP 3A4, a clinical study with rifampin, an inducer of CYP 3A4, showed no effect on the pharmacokinetics of fulvestrant.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-24
Safety of the active substance
From the US prescribing label for the same active substance (CLIGAVYX). It describes the substance, not this exact product.
- CLIGAVYX is contraindicated in patients with a known hypersensitivity to the drug or to any of its components.
- Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with CLIGAVYX [see Adverse Reactions (6.2) ].
The most frequently reported adverse reactions in the fulvestrant 500 mg group were injection site pain (11.6% of patients), nausea (9.7% of patients), and bone pain (9.4% of patients); the most frequently reported adverse reactions in the fulvestrant 250 mg group were nausea (13.6% of patients), back pain (10.7% of patients), and injection site pain (9.1% of patients).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
Spain13 matching products
- AMBIFUL 250 mg · solución inyectable en jeringa precargada
- FASLODEX 250 mg · solución inyectable en jeringa precargada
- FULVESTRANT DR. REDDYS 250 mg · solución inyectable en jeringa precargada
- FULVESTRANT EUGIA 250 mg · solución inyectable
- FULVESTRANT HIKMA 250 mg · solución inyectable en jeringa precargada
- FULVESTRANT MYLAN 250 mg · solución inyectable
- FULVESTRANT STADA 250 MG · solución inyectable
- FULVESTRANT SUN 250 mg · solución inyectable en jeringa precargada
France11 matching products
- FASLODEX 250 mg · solution injectable
- FULVESTRANT ACCORD 250 mg · solution injectable
- FULVESTRANT ARROW 250 mg · solution injectable
- FULVESTRANT BIOGARAN 250 mg · solution injectable
- FULVESTRANT EG 250 mg · solution injectable
- FULVESTRANT EG LABO 250 mg · solution injectable
- FULVESTRANT HIKMA 250 mg · solution injectable
- FULVESTRANT MYLAN 250 mg · solution injectable
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Fulvestrant |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 250 mg |
| Form | oplossing voor injectie |
| Classification | L02BA03 · Cancer treatments and immune-system medicines |
| Route | intramusculair gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | EU/1/03/269 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.